Tradeoffs

Journalist Paula Span, who writes The New Old Age column for the New York Times, shares what she’s learned about how to age well.Guest:Paula Span, reporter and The New Old Age columnist for the New York TimesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.

U.S. companies spend more than $1 trillion annually on health care for their employees. To get this budget-busting figure under control, some companies are experimenting with cutting out insurers, and investing in primary care clinics at the office.  Guests:Amy Cooper, NP, Vera Whole HealthBob Galvin, MD, former Chief Medical Officer, General Electric and Board Chairman, Catalyst for Payment ReformDan Mendelson, CEO, Morgan HealthAnn O’Malley, MD, MPH, Senior Fellow, MathematicaMatt Ohrt, Co-founder, Self Fund HealthLee Sagraves, Employee, JPMorganChaseGwen SagravesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.

For decades, the most effective treatment for addiction to methamphetamine or cocaine has been mired in stigma and mostly limited to small research studies. But with deaths involving meth and cocaine on the rise, policymakers across the country are turning to gift cards to fight drug use.This story has been updated to clarify the research on long-term effects of contingency management and the eligibility requirements to deliver contingency management through CalAIM.Credits:Stephen Higgins, PhD, Professor of Psychology and Psychiatry, University of VermontRichard Rawson, PhD, Professor Emeritus, UCLA Department of PsychologyAndrew Dertien, Contingency Management Coordinator, HealthRIGHT 360Bernard GrovesAyesha Appa, MD, Assistant Professor of Medicine, UCSF and San Francisco General HospitalTyler Sadwith, Medicaid Director, California Department of Health Care ServicesLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.

Many potent new medicines pose a host of challenges for drug companies trying to copy and sell similar versions on the cheap. Can those companies find a sustainable path forward, or will patients get left stuck paying exorbitant prices?Guests:Christine Baeder, MBA, President, Apotex USAAlfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical Industry AssociationJeremy Greene, MD, PhD, Professor of Medicine and the History of Medicine, Johns Hopkins UniversityCandy Meyer, PatientBhaven Sampat, PhD, Professor, Arizona State University School for the Future of Innovation in SocietyMarta Wosińska, PhD, Senior Fellow, Brookings InstitutionLeslie Walker, Senior Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.

America pays less, on average, than any other major country for our generic drugs. But selling essential drugs at such low prices comes with hidden costs — from quality problems to frequent shortages.This is the second episode of Race to the Bottom, a three-part series by Tradeoffs on the problems plaguing the generic drugs we all rely on — and how we could fix them.Guests:Christine Baeder, MBA, President, Apotex USALaura Bray, MBA, Founder, Angels for ChangeCraig Burton, Senior Vice President of Policy and Strategic Alliances, Association for Accessible MedicinesIilun Murphy, MD, Director of the Office of Generic Drugs, FDALeslie Walker, Senior Reporter/Producer, TradeoffsMarta Wosińska, PhD, Senior Fellow, Brookings InstitutionLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.

Generic drugs are, in many ways, the unsung hero of America’s health care system, bringing powerful medical innovations within the reach of millions more people. These cheaper copies of brand-name drugs — from pills that stop heart attacks to antibiotics that cure life-threatening infections — save America hundreds of billions of dollars a year. But will affordable, high-quality generic drugs continue to be there when we need them?Some players are abandoning this business while others slash costs by cutting dangerous corners. Shortages of older generic drugs have become the norm, sending doctors scrambling. At the same time, crucial new medicines are proving tougher to copy on the cheap, saddling patients with brand-name prices.Over the course of “Race to the Bottom,” our new three-part podcast series, we’ll explore why this industry that’s so essential to our health is in trouble — and what could change that.In part one, we examine the history of this industry. Forty years ago this month, President Ronald Reagan signed groundbreaking, bipartisan legislation that gave birth to a new drug market. Lawmakers made choices back then that help explain the wild success and also the troubles we see today with generic medicines.Guests:Christine Baeder, MBA, President, Apotex USAAlfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical AssociationLeslie Walker, Senior Reporter/Producer, TradeoffsLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift.